Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health
Open accessThe DOI matches its Crossref record; 66 of the 94 references it cites were found in a registry or an index, and 26 are not checked yet; 13 of the 82 sources its claims cite were checked for support.
Abstract
Twenty percent of deaths in the United States are secondary to cardiovascular diseases (CVD). In patients with hyperlipidemia and hypertriglyceridemia, studies have shown high atherosclerotic CVD (ASCVD) event rates despite the use of statins. Given the association of high triglyceride (TG) levels with elevated cholesterol and low levels of high-density lipoprotein cholesterol, the American Heart Association (AHA)/American College of Cardiology (ACC) cholesterol guidelines recommend using elevated TGs as a “risk-enhancing factor” for ASCVD and using omega 3 fatty acids (Ω3FAs) for patients with persistently elevated severe hypertriglyceridemia. Ω3FA, or fish oils (FOs), have been shown to reduce very high TG levels, hospitalizations, and CVD mortality in randomized controlled trials (RCTs). We have published the largest meta-analysis to date demonstrating significant effects on several CVD outcomes, especially fatal myocardial infarctions (MIs) and total MIs. Despite the most intensive research on Ω3FAs on CVD, their benefits have been demonstrated to cluster across multiple systems and pathologies, including autoimmune diseases, infectious diseases, chronic kidney disease, central nervous system diseases, and, most recently, the COVID-19 pandemic. A review and summary of the controversies surrounding Ω3FAs, some of the latest evidence-based findings, and the current and most updated recommendations on Ω3FAs are presented in this paper.
Verified 2026-10-05 · 26 references not checked yet
Overview
CoChat Summary
TL;DR
This review summarizes evidence and controversies on omega-3 polyunsaturated fatty acids (Ω3FAs) for cardiovascular health, covering mechanisms, dietary sources, the omega-3 index, and recent randomized and meta-analytic data. It concludes that higher-dose EPA/DHA may reduce major cardiovascular outcomes, especially myocardial infarction, and recommends 2 g/d EPA/DHA generally and 4 g/d for patients with ASCVD and hypertriglyceridemia.
Key findings
- In REDUCE-IT, 8,179 statin-treated patients with fasting triglycerides 135–499 mg/dL and LDL cholesterol 41–100 mg/dL received 2 g icosapent ethyl twice daily or placebo over 4.9 years; the primary composite endpoint occurred in 17.2% vs. 22.0% (HR 0.75; 95% CI 0.68–0.83; p < 0.001), and the secondary composite of CVD death, non-fatal MI, or non-fatal stroke occurred in 11.2% vs. 14.8% (HR 0.74; 95% CI 0.65–0.83; p < 0.001).
- A meta-analysis of 13 RCTs with 127,477 participants found marine Ω3 supplementation associated with lower MI (RR 0.92; 95% CI 0.86–0.99; p = 0.020), CHD death (RR 0.92; 95% CI 0.86–0.98; p = 0.014), total CHD (RR 0.95; 95% CI 0.91–0.99; p = 0.008), CVD death (RR 0.93; 95% CI 0.88–0.99; p = 0.013), and total CVD (RR 0.97; 95% CI 0.94–0.99; p = 0.015), even when excluding REDUCE-IT.
- An earlier meta-regression of 40 interventional trials with 135,267 participants found each 1 g/day increase in Ω3 associated with a 5.8% reduction in CVD events and a 9.0% reduction in MIs; the authors’ updated meta-analysis of 42 trials with nearly 150,000 participants found each 1 g/d increase in DHA and EPA associated with a 9% reduction in MI but no reduction in CVD events.
- The omega-3 index (O3I) of 8% was associated with decreased CHD mortality risk, while an O3I below 4% increased this risk; the AHA recommends 3 ounces of cooked fish twice weekly, yet NHANES reported a 6.8% decrease in Americans older than 20 consuming seafood more than once weekly between 2005–2006 and 2015–2016.
Methods
- Narrative review/update summarizing fundamentals, controversies, and current recommendations for Ω3FAs in cardiovascular and routine clinical practice, including dietary sources, molecular mechanisms, the omega-3 index, recent data, dosage, chronic kidney disease, heart failure, brain effects, and COVID-19.
- Evidence discussed includes RCTs (e.g., DART, GISSI-Prevenzione, OMEGA, REDUCE-IT, VITAL, JELIS, STRENGTH, GISSI-HF), meta-analyses/meta-regressions (10 trials with 77,917 participants; 13 RCTs with 127,477 participants; 40 trials with 135,267 participants; updated 42 trials with nearly 150,000 participants; 21 RCTs plus 1 observational study with 2,277 participants), and observational analyses (NHANES, MESA, MERLIN-TIMI 36, CKD cohort).
- Main analysis is a narrative synthesis of selected trial and meta-analysis results; no new primary data collection or formal systematic review methods are reported.
Limitations
- The paper states that studies surrounding Ω3FAs remain controversial, individual trial results are inconsistent, and heterogeneity may arise from differences in dosages, follow-up duration, sample sizes, and lower event rates; further RCTs are necessary.
- The paper notes specific limitations of cited studies: the OMEGA trial lacked statistical power and had reduced rates of SCD, total mortality, and MACE after one year; the COVID-19 O3I pilot study was underpowered and did not reach statistical significance.
- Evident from the text: this is a narrative review rather than a systematic review or meta-analysis, with no formal search strategy, inclusion criteria, risk-of-bias assessment, or quantitative pooling reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Percentage of adults aged 20 and over consuming seafood at least two times per week, by age and sex, in the United States in 2013–2016 [23].](https://figures.cochat.ai/paper-figures/885fe8d086124bf8b454e28e194ea08f/update-on-omega-3-polyunsaturated-fatty-acids-on-cardiovascular-health-figure-2.jpg)
![Figure 3 REDUCE-IT trial prespecified endpoints. The rates of all endpoints, except death from any cause, were significantly lower in icosapent ethyl (eicosapentaenoic acid ethyl esters). Data were adapted from NEJM [5] and reproduced with Mayo Clinic Proc [57] permission.](https://figures.cochat.ai/paper-figures/f6d336123efd4d41996ebfeeffce5e76/update-on-omega-3-polyunsaturated-fatty-acids-on-cardiovascular-health-figure-3.jpg)
![Figure 4 Pooled results from a meta-analysis. Pooled estimate of relative risk and 95% confidence interval, number of studies, and the combined number of participants. CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction [52].](https://figures.cochat.ai/paper-figures/0fefd1bcdcdf4717beb84bd93d0ebe8a/update-on-omega-3-polyunsaturated-fatty-acids-on-cardiovascular-health-figure-4.jpg)
Verification
Claims the paper makes
11 Valid · 0 Not valid · 56 Not checked · 13 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Fresh seafood with high n-3 PUFAs was 32% more expensive than fresh seafood with low n-3 PUFAs (p < 0.002).”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 3. Molecular Mechanisms
What the sources say
- Supportedcites [24] Love, 2022, Affordability influences nutritional quality of seafood consumption among income and race/ethnicity groups in the United States, Am. J. Clin. Nutr. source
The Results section, “Retail price and intake of seafood high in n–3 PUFAs,” states that fresh seafood high in n–3 PUFAs was 32% more expensive than fresh seafood low in n–3 PUFAs, with P < 0.002. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A diet low in Ω3FAs is associated with increased mortality and CHD risk [5,38,51,52]”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 5. Index
What the sources say
- Not checked yetcites [5] Bhatt, 2019, Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, N. Engl. J. Med. source
- Could not verifycites [38] Bhatt, 2020, REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States, Circulation sourceExperimental — accuracy not yet measured
The Methods describe a trial of icosapent ethyl versus placebo in statin-treated patients with elevated triglycerides, and the Discussion reports cardiovascular and mortality outcomes for those groups (page numbers unavailable). Searches for low dietary omega-3 intake and its association with mortality or CHD risk found no passage addressing that relationship. (LLM, conf=0.77)
- Partly supportedcites [51] Hu, 2019, Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127,477 Participants, J. Am. Heart Assoc. sourceExperimental — accuracy not yet measured
The Results report lower total CHD and CHD-death risk with marine omega-3 supplementation, and the Introduction notes an association between higher fish consumption and lower heart-disease risk. But the paper does not establish that a diet low in omega-3 fatty acids is associated with increased mortality overall; its mortality findings concern CHD and CVD deaths in supplementation trials. No page numbers are provided in our copy. (LLM, conf=0.86)
- Partly supportedcites [52] Bernasconi, 2021, Omega-3 Benefits Remain Strong Post-STRENGTH, Mayo Clin. Proc. sourceExperimental — accuracy not yet measured
In “Omega-3 Benefits Remain Strong Post-STRENGTH” (page not provided), the authors report lower CHD event risk and CHD mortality with EPA and DHA intake. That supports the direction of the CHD-risk claim, but the paper does not establish that a diet low in omega-3s increases overall mortality; its mortality findings are specific to CHD and fatal myocardial infarction. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“According to the study, Ω3FA supplements did not prevent fatal MIs and strokes in people with a high CVD risk [56].”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 6. Recent Data
What the sources say
- Supportedcites [56] Aung, 2018, Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77917 Individuals, JAMA Cardiol. source
The Discussion (p. Abstract/Discussion, passage 2) states that randomization to omega-3 FA supplementation over a mean of 4.4 years 'had no significant effect on either of fatal CHD, nonfatal MI, stroke, revascularization events, or any major vascular events,' and the Abstract Findings echo this for fatal coronary heart disease. The Abstract 'Meaning' section explicitly frames the population as 'people who have or at high risk of developing cardiovascular disease,' matching the citing sentence's high-CVD-risk qualifier. Interpreting 'fatal MIs' as the paper's fatal CHD endpoint is a faithful paraphrase. (LLM, conf=0.90)
plainn = 77,917- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“EPA's ability to stabilize cell membranes, along with its ability to lower cholesterol, may contribute to the 30% and 40% reductions seen in deaths from CVD and sudden cardiac death (SCD) and the 56% reduction in cardiac arrest [31].”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 3. Molecular Mechanisms
What the sources say
- Partly supportedcites [31] Gaba, 2022, Prevention of Cardiovascular Events and Mortality with Icosapent Ethyl in Patients with Prior Myocardial Infarction, J. Am. Coll. Cardiol. sourceExperimental — accuracy not yet measured
The Results (Study Population and Baseline Characteristics; page unavailable) report 30%, 40%, and 56% relative risk reductions in cardiovascular death, sudden cardiac death, and cardiac arrest, respectively, with icosapent ethyl among patients with prior myocardial infarction. The paper describes EPA-related membrane stabilization, but does not identify cholesterol lowering as an EPA mechanism contributing to these outcomes; it says the mechanistic basis remains unclear. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Based on a meta-analysis and meta-regression of 40 interventional trials involving 135,267 participants, Ω3 proved to have dose-dependent significant protective effects against CVD and MI [57].”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 7. Importance of Dosage
What the sources say
- Supportedcites [57] Bernasconi, 2021, Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials, Mayo Clin. Proc. source
The Characteristics of Included Studies section reports 40 trials with participant counts totaling 135,267. The Meta-Regression section reports statistically significant dose-dependent reductions in CVD events and MI with higher EPA and DHA dosages. (LLM, conf=0.92)
plainstates a causen = 135,267- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
35 more claims · 3 with their cited sources checked
Create a free account to see all 80 claims and to verify the 69 references still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 3
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, a meta-analysis of 90 RCTs (n = 72,598) demonstrated a dose-response relationship between omega-3 intake and reductions in triglycerides and non-HDL cholesterol, particularly in hyperlipidemia, overweight/obesity, or coronary heart disease, and more evident with doses >2 g/day or in those on lipid-lowering therapy [299].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [299]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 9. Heart Failure (HF)
“Hence the 2022 AHA/ACC guidelines for managing HF have outlined that Ω3FAs might be reasonably used as an adjunctive therapy on patients with HF class II-IV symptoms to reduce mortality and CVD hospitalizations [68].”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > References
“68. Mehra, M.R.; Lavie, C.J.; Ventura, H.O.; Milani, R.V. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J. Heart Lung Transplant. 2006, 25, 834-838. [CrossRef]”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 8. Chronic Kidney Disease (CKD)
“second (0.87-1.30g/day)”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 8. Chronic Kidney Disease (CKD)
“third (0.87-1.30g/day)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 2. Dietary Sources and Guidelines
“finding an inverse correlation of the O3I with CHD.”
§ Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health > 5. Index
“Its levels were demonstrated to have a direct correlation with the risk of death from CHD, where an O3I value of 8% decreased the risk of CHD mortality and a percentage less than 4% increased this risk [55].”
Citations
Cites
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Health inequalities among British civil servants: the Whitehall II study
Marmot, M. G., Stansfeld, S., Patel, C., North, F., Head, J., White, I., Brunner, E., Feeney, A., Marmot, M. G., & Smith, G. D. (1991) · The Lancet · doi:10.1016/0140-6736(91)93068-k · Cited by 3,608
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 9×
“, in the REDUCE-IT trial [5], used four times the dose of Ω3FAs (IPE 2 g twice daily) used in the VITAL trial.”
BackgroundMethodInfluentialBurr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610 · cited 1×
“The Diet and Reinfarction Trial (DART) [35] was the first RCT to show a reduction in mortality during the two years after myocardial infarction (MI) among men who were advised to eat about 300 g of FO per week or who took an equivalent amount of n-3 fatty acids in the form of FO supplements.”
BackgroundYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · cited 1×
“The Effects of EPA on Major CHD Events in Hypercholesterolemic Patients (JELIS) trial was a randomized, open-label, blinded endpoint analysis conducted in Japan between 1996 and 1999 [50].”
BackgroundTriglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419 · cited 1×
“Furthermore, as elevated triglycerides (TGs) appear to be a causal factor for atherosclerotic CVD (ASCVD) and possibly for premature all-cause mortality, more so when they are associated with genetic variants, PUFAs can reduce TG levels by decreasing lipoproteins with high amounts of TGs, such as very-low-density lipo…”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Serhan, C. N., & Levy, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97943 · Cited by 1,344 · cited 2×
“, obesity), diabetes, and autoimmune diseases [88].”
BackgroundImportance of n−3 fatty acids in health and disease
Connor, W. E. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.1.171s · Cited by 1,344
Cited by
The Ketogenic Diet and Cardiovascular Diseases
Dyńka, D., Kowalcze, K., Charuta, A., & Paziewska, A. (2023) · Nutrients · doi:10.3390/nu15153368 · Cited by 134
Khaksar, G., Kasemcholathan, S., & Sirikantaramas, S. (2024) · Horticulturae · doi:10.3390/horticulturae10040342 · Cited by 75
“These associations have been highlighted in studies by Breslow [38] and Rodriguez et al. [39].”
BackgroundFish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis
Lok, C. E., Farkouh, M., Hemmelgarn, B. R., Moist, L. M., Polkinghorne, K. R., Tomlinson, G., Tam, P., Tonelli, M., & Udell, J. A. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2513032 · Cited by 60
Larrosa, M., Gil‐Izquierdo, Á., González‐Rodríguez, L. G., Alférez, M. J. M., Juan, A. F. S., Sánchez-Gómez, Á., Calvo‐Ayuso, N., Ramos-Álvarez, J. J., Fernández‐Lázaro, D., López-Grueso, R., et al. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae082 · Cited by 67
Yang, Y., Xia, Y., Zhang, B., Li, D., Yan, J., Yang, J., Sun, J. P., Cao, H., Wang, Y., & Zhang, F. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1166702 · Cited by 49
Metadata
- Authors
- Rodriguez, D., Lavie, C. J., Elagizi, A., & Milani, R. V.
- Affiliations
- John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Ochsner Clinical School—The University of Queensland School of Medicine, New Orleans, LA 70121, USA
- Ochsner Health System (US)
- Corresponding author
- Lavie, Carl J.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2022-12-03
- Volume
- 14
- Issue
- 23
- Pages
- 5146
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC9739673
- OpenAlex
- W4310682235
- Cited by
- 81
- References
- 94
- Citations by year
- 2026: 10 · 2025: 22 · 2024: 23 · 2023: 26
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Keywords
- omega-3 polyunsaturated fatty acids, fish oil, cardiovascular disease, hypertriglyceridemia, atherosclerotic cardiovascular disease, triglycerides, myocardial infarction, statin therapy, hyperlipidemia, cardiovascular mortality, autoimmune disease, chronic kidney disease, central nervous system disorders, COVID-19 pandemic
- MeSH terms
- COVID-19, Cardiovascular Diseases, Cholesterol, Humans, Hyperlipidemias, Cholesterol, HDL, Myocardial Infarction, Triglycerides, United States, Hypertriglyceridemia, Fatty Acids, Omega-3, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.